BioLife Solutions Stock Today
| BLFS Stock | USD 18.85 -0.68 -3.48% |
Performance Weak
| Odds Of Distress Low
|
BioLife Solutions currently trades at $18.85, posting a 3.48% decrease in today's market action with an intraday range between $18.8 and $19.54. BioLife Solutions carries a 8% probability of financial distress over the medium term. Over the last 90 trading days, it has delivered negative risk-adjusted returns. The performance scores are derived for the period from December 21, 2025 through March 21, 2026. The scores are based on performance observations within the time window. Values are drawn from observed market activity across periods. Learn more.
IPO Date 22nd of November 1989 | Asset Type Stock | Category Healthcare | Classification Health Care |
Moving together with BioLife Stock
Moving against BioLife Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Stock Highlights
BioLife Solutions (BLFS) is listed on NASDAQ Exchange in USA. BioLife Solutions is categorized in the Health Care Equipment & Supplies sector. The company is classified under the Health Care Equipment & Supplies sector. At roughly 943.3 M, BioLife Solutions belongs to the small-cap segment of health care equipment & supplies companies. Useful market capitalization details here include about 48.3 M shares outstanding, enterprise value near 872.75 M, and a workforce of about 155 people. The company has 3 M shares sold short (7.14 days to cover). A negative net margin of 4.78% indicates the company is not currently profitable on a net income basis. The elevated P/E of 173.59 combined with ROE of -3.37% may reflect growth expectations beyond current return levels. The company reported previous year's revenue of 96.21 M. Net Loss for the year was -4.59 M with profit before overhead, payroll, taxes, and interest of 62.12 M. BioLife Solutions financial stability analysis Ownership Allocation The majority of BioLife Solutions' outstanding shares are owned by institutional investors. High institutional ownership often reflects the stock's eligibility for passive index funds, which are required to hold positions proportional to index weights regardless of their own investment view. Active managers holding BioLife Solutions must also disclose positions above certain thresholds through SEC filings. Institutions collectively hold about 97% of BioLife Solutions' shares, insiders own approximately 3%, and the remaining 0% is in public hands. Check BioLife Ownership DetailsBioLife Solutions Hype to Price Pattern
Public headlines and social activity around BioLife Solutions shape investor expectations in ways that translate into measurable risk signals for BioLife. Monitoring how BioLife Solutions' average sentiment shifts over time can inform when to add or reduce exposure. Investor mood toward BioLife Solutions is presently assessed as strongly positive, according to analysis of 1 media-driven sentiment signals as of 2026-02-27.
Open Interest Against 2026-04-17 BioLife Option Contracts
Current option-chain data for BioLife Solutions covers the April 17th 2026 expiration. The chain lists 18 contracts (9 calls and 9 puts). At a glance, metrics point to implied volatility near 1.74 and put/call open-interest ratio around 0.05. Strike-level open interest is available in the full chain. View more details.Options open interest data for BioLife Solutions reflects contract activity levels. These metrics are evaluated alongside changes in the underlying price. Variations in contract activity may reflect evolving positioning strategies.
ESG SustainabilityBioLife Solutions (BLFS) recorded an ESG Environmental Score of 58.84, an ESG Governance Score of 62.92, and an ESG Social Score of 62.50. BioLife Solutions' ESG indicators trend above peer averages in Health Care Equipment & Supplies. ESG factors can help frame long-term stability and stakeholder alignment. All metrics are presented as contextual information.
Environmental | Governance | Social |
Notable Updates
| CEO and President and Director | Michael Rice | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chairman | Aby Mathew | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Vice President of Marketing | Todd Berard | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Vice President - Operations | Karen Foster | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, SAMPP Small-Cap 600, NASDAQ Composite Total, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst RecommendationThe aggregated analyst view for BioLife Solutions equals 4.10 (Strong Buy) across 10 ratings. There is little change in overall analyst sentiment. Recent coverage changes contribute to this pattern. 10 of 10 analysts indicate buy-oriented ratings. This mix helps frame sentiment. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength BioLife Solutions (BLFS) recorded a Gross Profit Margin of 42.0%, an Operating Margin of -0.3%, and a Return On Assets of -3.1%. BioLife Solutions reflects a mix of operating scale and capital structure considerations. Current profitability metrics are under pressure, reflecting a period of reduced earnings capacity. Healthcare businesses are assessed through pipeline value, regulatory exposure, and cash burn relative to commercialization timelines.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBioLife Solutions (BLFS) recorded $1.70 in Net Debt To EBITDA, a Debt To Equity of 0.09x, and $7.8 million in Long Term Debt. Supporting metrics include a Long Term Debt To Capitalization of 2.7% and $2.3 million in Long Term Debt Total, which analysts use to evaluate BioLife Solutions's operational efficiency. Current AssetsBioLife Solutions (BLFS) recorded $0.33 in Intangibles To Total Assets, $426.2 million in Total Assets, and a Return On Assets of -3.1%. Supporting metrics include a Return On Tangible Assets of -6.6%, which analysts use to evaluate BioLife Solutions's operational efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings per Share Projection vs Actual
Consensus EPS for BioLife Solutions is 0.01, with bounds of 0.01 and 0.02. EPS TTM is -0.25. For BioLife Solutions, EPS is most informative when read together with margin stability and cash-flow conversion.
Consensus EPS projections for BioLife Solutions' are based on current analyst assumptions and may be revised. Reported EPS TTM is historical and should not be read as a forecast.
Top Institutional Holders
Institutional Holdings in BioLife Solutions captures the equity stake owned by major financial organizations such as mutual funds, pension plans, and endowments. These holders can acquire large positions in BioLife Solutions and exert significant management influence.| Instituion | Recorded On | Shares | |
| Royal Bank Of Canada | 2025-09-30 | 919.2 K | |
| Ameriprise Financial Inc | 2025-09-30 | 908.9 K | |
| Palisade Capital Management Llc | 2025-12-31 | 811 K | |
| Geneva Capital Management | 2025-12-31 | 803.5 K | |
| Rockefeller Capital Management L.p. | 2025-12-31 | 705.9 K | |
| Stephens Inv Mgmt Group Llc | 2025-12-31 | 606.9 K |
BioLife Solutions Historical Income Statement
Based on recent performance metrics, Depreciation And Amortization is expected to increase significantly. BioLife Solutions last posted Depreciation And Amortization of 9.96 Million. As of March 21st, 2026, Research Development is estimated to rise to approximately 7.9 M, whereas EBIT is moving lower toward slightly above -6.7 M. View More FundamentalsBioLife Solutions Against Markets
Stock Overview, Methodology & Data Sources
develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. was incorporated in 1987 and is headquartered in Bothell, Washington. BioLife Solutions employs 155 people. Headquarters are in 3303 Monte Villa Parkway, Bothell, WA, United States, 98021. Latest reported figures include market cap 943.3 M, P/E 173.59, P/B 2.54. BioLife Solutions operates in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care. This section focuses on fundamentals first, then market-implied risk context. Price behavior may show elevated responsiveness to broader market cycles.
Methodology
Unless otherwise specified, financial data for BioLife Solutions is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. BioLife (USA Stocks:BLFS) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Underlying inputs rely on public filings and market reference sources, including disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Values may reflect publication timing differences. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
BioLife Solutions has active sell-side coverage. Source-validated coverage currently shows 10 approved analysts, while broader market-consensus totals may differ across providers due to methodology and update timing. 5 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include HSBC Global Research, Wells Fargo Securities, Goldman Sachs, Guggenheim Securities, RBC Capital Markets, Citigroup, among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardBioLife Solutions Corporate Management
| Sarah JD | Chief Officer | Profile | |
| Troy Wichterman | Chief Officer | Profile | |
| Geraint Phillips | Senior Operations | Profile | |
| Troy CPA | Chief Officer | Profile |
Additional Tools for BioLife Stock Analysis
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |